Market Overview

UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals

Share:
Related DGX
Benzinga's Top Initiations
Barclays Initiates Quest Diagnostics With Equalweight
Outpatient, Home Healthcare Set to Gain: 3 Picks - Analyst Blog (Zacks)

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.

In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”

Quest Diagnostics closed on Wednesday at $57.30.

Latest Ratings for DGX

DateFirmActionFromTo
Mar 2015Canaccord GenuityUpgradesHoldBuy
Mar 2015BarclaysInitiates Coverage onEqualweight
Feb 2015Bank of AmericaDowngradesNeutralUnderperform

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (DGX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content